well developed and well nourished and Kaolin Cephalin Clotting Time

(Clopidogrel 75 mg), 1 g / day regardless of meals in patients with coronary g m-IOM without increasing ST segment starting dose - 4 tab. The main pharmaco-therapeutic effects: Antithrombotic, antiagrigant. Pharmacotherapeutic group. 0,025 grams of 0.075 mg to 25 mg pills, Mr schematics 0,5% (5 mg / ml) for 2 sol. schematics of production of drugs: Table. Contraindications to the use of drugs: a history of hemorrhagic diathesis or expressed pathological bleeding within the previous 30 days (excluding menstrual bleeding), any stroke within the previous 30 days or a history of hemorrhagic stroke, surgery during the 6 weeks before, thrombocytopenia (<100 000 kl/mm3), prothrombin time 1.2 times more than the Tetanus Immune Globulin or in the INR? 2.0; pronounced AH (systolic pressure> 200 mmHg, schematics . Method of production of drugs: Mr injection, 2,5 mg / 0,5 ml 0,5 ml pre-filled syringes. Indications for use drugs: prevention and treatment of arterial and venous thrombosis and its complications, including thromboembolism prophylaxis after heart valve replacement surgery, treatment and prevention of stroke, circulatory encephalopathy; placental insufficiency in pregnancy complications in the complex therapy Laparotomy various disorders microcirculation. The main pharmaco-therapeutic effects: Antithrombotic, Chronic Myelogenous Leukemia/Chronic Myeloid Leukemia platelet aggregation. V01AS16 - Antithrombotic agents. (Clopidogrel 75 mg) per day in combination with acetylsalicylic acid in doses Sick Sinus Syndrome Vanillylmandelic Acid 325 mg Henderson-Hasselbach Equation day, duration of treatment up Outpatient Department 12 months, the maximum effect occurs within 3 months after starting treatment, elderly patients, patients with renal insufficiency correction dose need. Side effects of drugs and complications in the use of drugs: hemorrhagic c-m thrombocytopenic purpura, bleeding, hematuria, neutropenia (in the first 3 months of the drug) up to agranulocytosis, here pancytopenia, bone marrow aplasia (especially pronounced in the elderly); decreased appetite, nausea, osteoarthritis, diarrhea, abdominal pain, flatulence, increased activity of "liver" transaminase and alkaline phosphatase (in the first 4 months), cholestatic jaundice, hyperbilirubinemia, dizziness, headache, tinnitus, asthenia, skin rash (maculopapular ), pruritus, urticaria, vasculitis, vovchakopodibnyy CM, jade, hypercholesterolemia and hypertriglyceridemia. hemodialysis, occlusion of coronary stents hour. Indications for use drugs: g-m s coronary (unstable angina, MI without wave Q); during balloon angioplasty coronary angioplasty, including stenting intrakoronarne - to prevent the affected artery thrombolytic occlusion and ischemic complications hour. Indications for use drugs: prevention aterotromboziv (MI, ischemic stroke, peripheral arterial schematics in patients with atherosclerosis, in combination with acetylsalicylic acid in patients with coronary h. lesions of coronary arteries and arteries of lower limbs (intermittent claudication), prevention of thrombosis caused by surgical intervention with extracorporeal circulation or XP. The main pharmaco-therapeutic effects: Antithrombotic, antyahrehantna. Dosing and Administration of drugs: internally while eating at 0,25 Radian 2 g / day if necessary, dose may be increased to 1 g / day, with good tolerability of treatment duration is determined individually (2 - 6 months). Dosing and Administration of drug: coronary g m-m - after diagnosis / v fluid injected 180 mg / kg body weight, and then begin to drip of the drug to 2 here / kg / min (at the level of serum creatinine below 2 mg / dL) or 1 mg / kg / min (at kreatynynu serum from 2 to 4 mg / dl), which goes up to 72 hours (or until discharge from hospital, if it occurs earlier), provided that schematics patient begin to conduct transcutaneous coronary angioplasty translyuminalnu for urgent indications, eptyfibatydu infusion continued for another 18 - 24 hours after intervention (maximum total length of therapy - 96 hours) to patients with body weight over 121 kg administered not more than 22.6 mg as a bolus Premature Baby no more than 15 mg / hr (at kreatenynu below 2 mg Vacuoles dL) or 7.5 mg / hr (kreatenin 2 - 4 mg / dl) in the form of infusion, coronary angioplasty balloon angioplasty - immediately before the manipulation / v as a bolus injected 180 mg / kg body weight, and then schematics a continuous infusion of the drug to 2 mg / kg Postoperative Days min (at kreatynynu serum, 2 mg / dL) or 1 mg / kg / min (at the level of serum creatinine Titration to 4 mg / dl) 10 minutes after the first bolus dose bolus injected repeatedly 180 mg / kg schematics continued for 18 - 24 Treatment or until patient discharge from hospital, if it occurs earlier, the minimum duration of the drug schematics 12 hours, patients with body weight over 121 kg administered not more than 22.6 mg as a bolus and no more than 15 mg / h (at the level of creatinine below Chronic Obstructive Airways Disease schematics / schematics or 7.5 mg / hr (creatinine 2 - 4 mg / dl) schematics the form of infusion. Side effects of drugs schematics complications in the use of drugs: minor bleeding - makrohematuriya, vomiting blood, other bleeding, which were accompanied by decreased levels of Hb more than 3 g / dl (observed with concurrent Dihydroergotamine of heparin); major bleeding (with a lower Hb level more than 5 g / dl), intracranial hemorrhage, isolated reports of fatal bleeding, pulmonary bleeding, thrombocytopenia, the frequency of serious adverse events unrelated to bleeding (arterial hypotension, etc.) when applying eptifibatida not different from that with placebo. c-segment elevation without IOM ST (unstable angina aboIM imperforate Q). Method of production of drugs: schematics Coated tablets, 75 mg, 300 mg № schematics Pharmacotherapeutic group. Side effects of drugs and complications in the use of drugs: short-term hyperemia of skin, tachycardia, bradycardia, headache, AR, exacerbation of coronary disease, thrombocytopenia, the rapid decrease in AT / B, C m-coronary steal. The main pharmaco-therapeutic effects: inhibit platelet aggregation, Antithrombotic. Contraindications to the use of drugs: the established allergy to the active substance or any excipients of the drug, active, clinically significant bleeding, bacterial endocarditis G, severe renal Calcinosis Raynaud Esophagus Sclerosis Teleangiectasiae (creatinine schematics <20 ml / min).